Tesaro Overview
- Founded
- 2010
- Status
- Acquired/Merged
- Employees
- 715
- Latest Deal Type
- M&A
- Latest Deal Amount
- $5B
Tesaro General Information
Description
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.
Contact Information
Primary Office
- 1000 Winter Street
- Waltham, MA 02451
- United States
Tesaro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 22-Jan-2019 | $5B | 00.000 | 000 | Completed | Profitable |
| 8. Secondary Transaction - Open Market | 01-Jun-2018 | 00.000 | Completed | Profitable | ||
| 7. PIPE | 01-Jan-2018 | 00000 | 00.000 | Completed | Generating Revenue | |
| 6. 2PO | 01-Jul-2016 | 00000 | 00000 | Completed | Generating Revenue | |
| 5. PIPE | 18-Apr-2016 | 00000 | 00000 | Completed | Generating Revenue/Not Profitable | |
| 4. 2PO | 27-Feb-2013 | 0000 | 00000 | Completed | Generating Revenue/Not Profitable | |
| 3. IPO | 28-Jun-2012 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 2. Early Stage VC (Series B) | 21-Jun-2011 | $101M | $121M | 00000 | Completed | Product Development |
| 1. Early Stage VC (Series A) | 26-May-2010 | $20M | $20M | 000.00 | Completed | Product Development |
Tesaro Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.00 |
Tesaro Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successfu
Pharmaceuticals
Waltham, MA
715
As of 2017
00.000
00
0000-00-00
000000&0
00.000
000000 0
dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000000000000
San Francisco, CA
000
As of 0000
00.000
000000000
00.000
00000000
sequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000 000000000
Baton Rouge, LA
000000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialTesaro Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
| 0000000000 | Corporate Backed or Acquired | Baton Rouge, LA | 000000000000 | |||
| 0000000 0000000000 | Formerly VC-backed | Beijing, China | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.00 | 00000000000 | 00.00 |
| 000000000 00000000 | Corporation | Bethesda, MD | 00 | 00000 | 000000000 - | 00000 |
Tesaro Patents
Tesaro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3860988-A1 | Crystalline forms of niraparib freebase | Pending | 03-Oct-2018 | 0000000000 | |
| EP-3860981-A1 | Niraparib salts | Pending | 03-Oct-2018 | 0000000000 | |
| US-20210346497-A1 | Methods of treating cancer | Pending | 04-Sep-2018 | 00000000000 | |
| AU-2019215450-A1 | Pediatric niraparib formulations and pediatric treatment methods | Pending | 05-Feb-2018 | 0000000000 | |
| CA-3090479-A1 | Pediatric niraparib formulations and pediatric treatment methods | Pending | 05-Feb-2018 | A61K31/454 |
Tesaro Executive Team (16)
Tesaro Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Beth Seidenberg MD | Kleiner Perkins | Board Member | 000 0000 |
| David Mott | Self | Chairman | 000 0000 |
| Earl Collier JD | Self | Board Member | 000 0000 |
| Garry Nicholson | Self | Board Member | 000 0000 |
| James Armitage MD | Tesaro | Board Member | 000 0000 |
Tesaro Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialTesaro Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Ally Bridge Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Athyrium Capital Management | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Australia Future Fund | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
| BB Biotech | Asset Manager | Minority | 000 0000 | 000000 0 | |
| BioPharma Credit | Other | Minority | 000 0000 | 000000 0 |
Tesaro Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 08-Jan-2018 | 00000 0000 | 0000 | Biotechnology | 0000 0000 |
Tesaro Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 | 08-Jan-2018 | 00000 00000 00 | 0000 | Completed |
|